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database. Twenty-two FDA-approved candidate drugs shifted the 
transcriptome similarly to ADSC treatment; and are thereby 
promising for RF treatment. Drug screening revealed that 
candidates which upregulate lipid metabolism or 
gluconeogenesis decreased collagen production and/or secretion 
by TGF-B stimulated fibroblasts.  
Conclusions: ADSC transplantation may be an effective 
treatment for the reversal of RF via metabolic reprogramming. 
Through pharmacogenomics analysis, we identified FDA 
approved drugs with potential to be repurposed for the 
treatment of RF based on their potential to induce metabolic 
alterations similar to ADSCs. Our data highlights the importance 
of metabolic dysregulation in the pathogenesis of RF and the 
importance of targeting these pathways in reversing RF. 
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Purpose: The mutational landscape of anal cancers has not been 
well studied. The purpose of this study was to perform the first 
analysis characterizing the types and frequencies of mutations in 
anal cancers from patients treated with radical 
chemoradiotherapy (CRT) using comprehensive next-generation 
sequencing (NGS). 
Methods and Materials: Pre-treatment formalin-fixed, paraffin-
embedded anal cancer specimens from 30 patients treated with 
radical CRT for anal cancer at a single tertiary institution were 
evaluated. Ninety percent of cases were squamous cell cancers. 
M:F ratio was 1:2.3; median patient age was 56 years (range: 34-
80): 47% (n = 14) had T2 disease. Tumour DNA was extracted and 
assayed for 50 oncogenes and tumour suppressor genes using the 
Ampliseq Cancer Hot Spot Panel (CHPv2) on the Ion PGM using a 
316v2 chip. Mean depth of target coverage was 1005X. 
Bioinformatic analysis was performed using Torrent Suite 
Software version 5.03. Variants from reference hg19 were called 
using variant Caller plugin 5.03.5 and annotated with Ion 
Reporter Software 5.0. All variants were manually reviewed 
using Broad Institute’s Integrative Genomics Viewer. Mutational 
status was determined and associated with HPV status. 
Results: Twenty-five of 30 cases (83%) were evaluable for full 
mutational analysis. The most common mutation identified was 
PIK3CA (4/25 of cases, 16%); 75% (3/4) were in exon 9. Overall, 
Pi3K/AKT/mTOR pathway activating mutations were seen in 24% 
(6/25 of cases). Other mutations were very rare: FBXW7 (n = 1, 
4%), p53 (n = 1, 4%), IDH1 (n = 1, 4%). One tumour had NRAS 
mutation; notably all other MAPK pathway genes were wild-type. 
Twenty-one of 25 cases were HPV sub-typed; 90% (19/21) were 
positive for high-risk HPV. Only p53 mutation was associated with 
HPV negative status. 
Conclusions: Pi3K/AKT/mTOR activating mutations were the 
most frequently observed in patients with anal cancer treated 
with CRT. Anal cancers have targetable mutations, making them 
amenable for consideration of therapeutics such as Pi3K and 
EGFR inhibitors. Validation with a larger data set will be 
undertaken to confirm these findings, and to determine their 
association with clinical outcome parameters. 
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Purpose: The immune microenvironment within tumours is 
critical to oncogenesis, cancer progression, and radiotherapy 
(RT) efficacy. Immunohistochemistry (IHC) is a convenient and 
inexpensive method by which to characterize the immune 
infiltrates in pathology samples. However, manually reading 
multiple IHC stains on tissue microarrays (TMA) is labor intensive 
and subject to bias. Our objective is to apply computer image 
analysis tools to localize and quantify immune markers in oral 
cavity squamous cell carcinoma (OCSCC) samples and determine 
their prognostic implications. 
Methods and Materials: A 91-patient OCSCC TMA was stained for 
the markers: CD3, CD4, CD8, FOXP3, IDO, and PD-L1. Tissue 
Studio (Definiens AG, Munich, Germany) was used to enumerate 
the number of marker-positive cells and to quantify the staining 
intensity for IDO and PD-L1. Cell populations were assigned to 
stromal or epithelial (tumour) compartments according to a mask 
derived from a pan-cytokeratin stain using a custom Matlab 
script. Automated methods were validated against manual tissue 
segmentation, cell count and stain intensity quantification. 
Univariate associations of cell counts and stain intensities with 
smoking status, TNM stage, overall survival (OS), and disease-
free survival (DFS) were determined. 
Results: 80.6% (737/910) of TMA cores were suitable for analysis, 
39.8% (35/88) of patients had a known never-smoker history, and 
34.1% (31/91) of patients were treated with RT. Comparison of 
automated to manual tissue segmentation showed good 
agreement (Kappa coefficient range: 0.61- 0.75). Automated and 
manual cell counts and stain intensities were highly correlated 
(Pearson correlation coefficient range: 0.46 - 0.91, p < 0.001 for 
all). Individual cell counts and stain intensities within the 
stromal, epithelial, or combined compartments did not display 
significant association with stage, OS or DFS in the set of all 
patients and in the subset of patients who received RT (p ≥ 0.05). 
Compared to never-smokers, current and ex-smokers had an 
increased density of FOXP3 cells in the epithelial compartment 
(OR 12.49, p = 0.06), and stronger PD-L1 stain intensity in both 
epithelial and stromal compartments (OR 4.54, p = 0.08; OR 6.58, 
p = 0.05); these results were confirmed by manual scores. 
Conclusions: Computer-assisted image analysis can be used for 
robust quantification of cellular populations by IHC. Our 
automated methods show that current and ex-smokers have 
higher density of FOXP3 cells in the epithelial compartment and 
have more intense PD-L1 staining in both epithelial and stromal 
compartments. This result is validated with manual IHC scoring. 
This proof-of-principle study demonstrates the utility of 
computer-assisted image analysis for high-throughput 
assessment of multiple IHC markers on TMAs, with potential 
implications for studies on prognostic and predictive biomarkers.  
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Purpose: Early studies have suggested a correlation between 
fluorodeoxyglucose-positron emission tomography (FDG-PET) 
uptake and epidermal growth factor receptor (EGFR) mutation 
status in patients with non-small cell lung cancer (NSCLC). 
Results from these few studies are conflicting and limited by 
small subject numbers. The purpose of this study was to 
determine if such a correlation exists in a large population using 
standardized diagnostic protocols. 
Methods and Materials: A retrospective review was conducted 
of patients with metastatic non-squamous, non-neuroendocrine, 
NSCLC who had EGFR mutation testing and FDG-PET imaging 
between March 2010 and March 2012. All patients had FDG-PET 
imaging at a central facility using the same scanning protocol. 
Data was collected on the maximum standardized uptake value 
(SUVmax) of the primary lung tumour. EGFR mutation testing was 
done at a central lab using a rapid polymerase chain reaction-
based detection technique. Patients were divided into EGFR 
mutation positive (EGFR+) and EGFR wild type (WT) cohorts. 
